Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • Bitcoin USD

    63,831.11
    -711.94 (-1.10%)
     
  • CMC Crypto 200

    1,327.58
    -68.95 (-4.94%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • Dow

    38,239.66
    +153.86 (+0.40%)
     
  • Nasdaq

    15,927.90
    +316.14 (+2.03%)
     
  • Gold

    2,349.60
    +7.10 (+0.30%)
     
  • Crude Oil

    83.66
    +0.09 (+0.11%)
     
  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

Novavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the coronavirus vaccine race. To make matters worse, earlier this year, Novavax even questioned its ability to continue operations. Jacobs revealed details about his strategy to cut costs, manage cash flow, and match Novavax's size to the demand for its only product: the coronavirus vaccine.